🇺🇸 FDA
Pipeline program

MESNA, MESNA, KEYTRUDA 25 mg/mL concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Fludarabine Teva 25 mg/ml concentraat voor oplossing voor injectie of infusie, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Endoxan, KEYTRUDA 25 mg/mL concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Endoxan 1000 mg milteliai injekciniam tirpalui, Proleukin 18 x 106 IE Poeder voor oplossing voor injectie of infusie, Cycloph

IOV-MEL-301

Phase 3 small_molecule active

Quick answer

MESNA, MESNA, KEYTRUDA 25 mg/mL concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Fludarabine Teva 25 mg/ml concentraat voor oplossing voor injectie of infusie, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Endoxan, KEYTRUDA 25 mg/mL concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Endoxan 1000 mg milteliai injekciniam tirpalui, Proleukin 18 x 106 IE Poeder voor oplossing voor injectie of infusie, Cycloph for Melanoma is a Phase 3 program (small_molecule) at Iovance Biotherapeutics B.V. with 1 ClinicalTrials.gov record(s).

Program details

Company
Iovance Biotherapeutics B.V.
Indication
Melanoma
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials